The Cleveland Clinic Taussig Cancer Institute entered into a research collaboration with Tempus, a health tech company focused on personalized oncology care.
Under the research collaboration, Tempus will provide molecular sequencing and analysis services to patients enrolled in a Taussig Cancer Institute-run precision oncology clinical study. The study's investigators will use this information to attempt to identify targeted therapies or clinical trials for patients with metastatic or incurable cancers.
"Incorporating advanced genomic data may enhance our ability to analyze vast amounts of clinical and molecular data, as we seek to improve the treatment options for our patients," said Brian J. Bolwell, MD, chairman of the Taussig Cancer Institute.